Nuevo tratamiento para la Histiocitosis: combinación de quimioterapia (en bajas dosis) y terapias target (inhibidores BRAFV600e).
New treatment for Histiocytosis patientscombinig chemotherapy (in low doses) and target therapies (BRAFV600e inhibitors).
Nuevo tratamiento combinado:
Dr. Dmitry Evseev publicó este novedoso estudio “Vemurafenib combined with cladribine and cytarabine results...
We award scholarships to doctors and scientists to attend the 40th Congress of the Histiocyte Society in GOA- India.
Selection of candidates:
The selection process for candidates is carried out and managed through the Histiocyte Society, following the submission of abstracts (scientific papers) on the congress' website.
Yesterday, August 13, 2024, the OR Association and its president,...
OR ASOCIACIÓN FINANCIA OTRA INVESTIGACIÓN SOBRE LA HISTIOCITOSIS EN ARGENTINA.
UN CONVENIO DE COLABORACIÓN CON EL INSTITUTO DE FARMACOLOGÍA DE LA FACULTAD DE MEDICINA DE LA UNIVERSIDAD DE BUENOS AIRES Y CON LA FUNDACIÓN NATALÍ DAFNE FLEXER.
Desde 2014 llevamos aportados a la investigación de la Histiocitosis más de 130.000€ repartidos en cuatro estudios que financiamos.
OBJETIVO DEL CONVENIO...
OR ASSOCIATION FUNDS ANOTHER HISTIOCYTOSIS RESEARCH PROJECT IN ARGENTINA.
COLLABORATION AGREEMENT WITH THE PHARMACOLOGY INSTITUTE OF THE FACULTY OF MEDICINE, UNIVERSITY OF BUENOS AIRES, AND THE NATALI DAFNE FLEXER FOUNDATION.
Since 2014, we have contributed over €130,000 to histiocytosis research, distributed across four studies that we have funded.
OBJECTIVE OF THE COLLABORATION...
